Format

Send to

Choose Destination
J Allergy Clin Immunol. 2019 Jul;144(1):339-342. doi: 10.1016/j.jaci.2019.03.025. Epub 2019 Apr 6.

Allogeneic hematopoietic stem cell transplant outcomes for patients with dominant negative IKZF1/IKAROS mutations.

Author information

1
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio. Electronic address: erinn.kellner@cchmc.org.
2
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio.
3
Immunology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Md.
4
Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
5
Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
6
Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Inserm UMR 1163, Paris, France; Clinical Immunology Department, Hôpital Saint Louis, Assistance Publique Hôpitaux de Paris (APHP) Université Paris Diderot, Paris, France.
7
Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Inserm UMR 1163, Paris, France; University Paris Descartes Sorbonne Paris Cité, Imagine Institut, Paris, France.
8
Department of Pediatric Immunology, La Timone Hospital, Marseille, France.
9
Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, Marseille, France.
10
Norwegian National Unit for Newborn Screening, Oslo University Hospital, Oslo, Norway.
11
Section of Specialized Pediatric Medicine, Oslo University Hospital, Rikshospitalet, Norway.
PMID:
30965037
DOI:
10.1016/j.jaci.2019.03.025

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center